A Randomized Double-Blind Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Brief description of study

To determine if adding atezolizumab to a paclitaxel, trastuzumab, and pertuzumab improves survival.


Clinical Study Identifier: s19-01008
ClinicalTrials.gov Identifier: NCT03199885
Principal Investigator: Nina D'Abreo.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.